B-RAF with PLX4032: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:
<scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br>
<scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br>
<scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br>
<scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br>
<scene name='B-RAF_with_PLX4032/H-bond/2'>H-Bond Interaction Asp594 and PLX4032</scene><br>
<scene name='B-RAF_with_PLX4032/H-bond/3'>H-Bond Interaction Asp594 and PLX4032</scene><br>
<scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br>
<scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br>
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br>
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br>

Revision as of 21:13, 7 October 2010

B-RAF with PLX4032B-RAF with PLX4032

PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.












testcaption

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Jens Hemmingsen, J.D. Woodruff, Michal Harel